Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 13 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 10993956

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  2. US 10993967

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  3. US 10987336

    Method of preventing or treating side effect of tumor therapy

    ONQUALITY PHARMACEUTICALS CHINA LTD. · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  4. US 10980788

    Therapy for treating malignancies

    Agios Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  5. US 10980868

    VEGFR-2 targeting immunotherapy approach

    Vaximm AG · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  6. US 10980848

    Antimicrobial therapy

    The Regents of the University of California · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  7. US 10983128

    CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

    Providence Health & Services · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  8. US 10981866

    Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  9. CN 112638413

    Oral immunotherapy unit dose dispensing systems and methods

    ALLERGEN RES CORPORATION · Granted Apr 9, 2021 · Expires Apr 4, 2041

    granted
  10. US 10954304

    Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

    The Regents of the University of California · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  11. US 10953046

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  12. US 10953047

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  13. US 10946000

    Method for treating cancer with combination therapy

    RedHill Biopharma Ltd. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  14. US 10946045

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  15. US 10946080

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  16. US 10946044

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  17. US 10940160

    Biomarkers for predicting responsiveness to decitabine therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  18. US 10940133

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    Jazz Pharmaceuticals Ireland Limited · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  19. US 10933076

    Crocin-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  20. US 10934334

    Peptides for angiogenic therapy

    The Regents of the University of California · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  21. US 10934550

    Immunotherapy of cancer

    Phio Pharmaceuticals Corp. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  22. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  23. US 10935554

    Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  24. US 10925928

    Method for treating chemotherapy-induced male infertility

    The Board of Regents of the University of Texas System · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted